Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 494 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment July 7, 2020 ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... November 17, 2022 ESMO Virtual Congress 2020, 19-21 September [ESMO Media Alert] July 27, 2020 FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma November 13, 2024 Load more HOT NEWS FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with... Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... Hormone Therapy Has A Stronger Impact On A Woman’s Quality Of... FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer
